These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 20331578)

  • 21. Safety of gadobutrol, a new generation of contrast agents: experience from clinical trials and postmarketing surveillance.
    Voth M; Rosenberg M; Breuer J
    Invest Radiol; 2011 Nov; 46(11):663-71. PubMed ID: 21623211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new Poisson and Bayesian-based method to assign risk and causality in patients with suspected hepatic adverse drug reactions: a report of two new cases of ticlopidine-induced hepatotoxicity.
    Zapater P; Such J; Pérez-Mateo M; Horga JF
    Drug Saf; 2002; 25(10):735-50. PubMed ID: 12167069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug rechallenge following drug-induced liver injury.
    Hunt CM; Papay JI; Stanulovic V; Regev A
    Hepatology; 2017 Aug; 66(2):646-654. PubMed ID: 28295448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence and prevalence of abnormal liver associated enzymes in patients with atrial fibrillation in a routine clinical care population.
    Makar GA; Weiner MG; Kimmel SE; Bennett D; Burke A; Yang YX; Han X; Sellers K; Nessel L; Lewis JD
    Pharmacoepidemiol Drug Saf; 2008 Jan; 17(1):43-51. PubMed ID: 17960855
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Time Series Analysis of the Effectiveness and Safety of Capsule Endoscopy between the Premarketing and Postmarketing Settings: A Meta-Analysis.
    Iijima K; Umezu M; Iwasaki K
    PLoS One; 2016; 11(6):e0153662. PubMed ID: 27248140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Background incidence of liver chemistry abnormalities in a clinical trial population without underlying liver disease.
    Weil JG; Bains C; Linke A; Clark DW; Stirnadel HA; Hunt CM
    Regul Toxicol Pharmacol; 2008 Nov; 52(2):85-8. PubMed ID: 18585425
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tolerability of atorvastatin in a population aged > or =65 years: a retrospective pooled analysis of results from fifty randomized clinical trials.
    Hey-Hadavi JH; Kuntze E; Luo D; Silverman P; Pittman D; Lepetri B
    Am J Geriatr Pharmacother; 2006 Jun; 4(2):112-22. PubMed ID: 16860258
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals.
    Lammert C; Einarsson S; Saha C; Niklasson A; Bjornsson E; Chalasani N
    Hepatology; 2008 Jun; 47(6):2003-9. PubMed ID: 18454504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An official ATS statement: hepatotoxicity of antituberculosis therapy.
    Saukkonen JJ; Cohn DL; Jasmer RM; Schenker S; Jereb JA; Nolan CM; Peloquin CA; Gordin FM; Nunes D; Strader DB; Bernardo J; Venkataramanan R; Sterling TR;
    Am J Respir Crit Care Med; 2006 Oct; 174(8):935-52. PubMed ID: 17021358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Causality assessment of liver injury after chronic oral amiodarone intake.
    Llanos L; Moreu R; Peiró AM; Pascual S; Francés R; Such J; Horga JF; Pérez-Mateo M; Zapater P
    Pharmacoepidemiol Drug Saf; 2009 Apr; 18(4):291-300. PubMed ID: 19165760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of black box warning by mining patterns of Convergent Focus Shift in clinical trial study populations using linked public data.
    Ma H; Weng C
    J Biomed Inform; 2016 Apr; 60():132-44. PubMed ID: 26851401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Postmarketing evaluations help determine contraceptive safety, efficacy.
    Netw Res Triangle Park N C; 1988; 9(2):1-2, 7. PubMed ID: 12280950
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis.
    Sokolove J; Strand V; Greenberg JD; Curtis JR; Kavanaugh A; Kremer JM; Anofrei A; Reed G; Calabrese L; Hooper M; Baumgartner S; Furst DE;
    Ann Rheum Dis; 2010 Sep; 69(9):1612-7. PubMed ID: 20448284
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antituberculosis drug-induced liver injury in chronic hepatitis and cirrhosis.
    Park WB; Kim W; Lee KL; Yim JJ; Kim M; Jung YJ; Kim NJ; Kim DH; Kim YJ; Yoon JH; Oh MD; Lee HS
    J Infect; 2010 Oct; 61(4):323-9. PubMed ID: 20670648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis].
    Kaneko Y; Nagayama N; Kawabe Y; Shimada M; Suzuki J; Kunogi M; Matsui Y; Kawashima M; Suzuki J; Ariga H; Oshima N; Masuda K; Matsui H; Nagai H; Tamura A; Akagawa S; Toyoda E; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2008 Jan; 83(1):13-9. PubMed ID: 18283910
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histologic evidence of active liver injury in chronic hepatitis B patients with normal range or minimally elevated alanine aminotransferase levels.
    Hu KQ; Schiff ER; Kowdley KV; Min AD; Shiffman ML; Lee WM; Goodman ZD; Dau LO; Peschell KJ; Fagan EA; Flaherty JF
    J Clin Gastroenterol; 2010 Aug; 44(7):510-6. PubMed ID: 20179614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment.
    Fetterly GJ; Owen JS; Stuyckens K; Passarell JA; Zannikos P; Soto-Matos A; Izquierdo MA; Perez-Ruixo JJ
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):135-47. PubMed ID: 17922277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients.
    Newman C; Tsai J; Szarek M; Luo D; Gibson E
    Am J Cardiol; 2006 Jan; 97(1):61-7. PubMed ID: 16377285
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors.
    Dieterich DT; Robinson PA; Love J; Stern JO
    Clin Infect Dis; 2004 Mar; 38 Suppl 2():S80-9. PubMed ID: 14986279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An integrated analysis of liver safety data from orlistat clinical trials.
    Morris M; Lane P; Lee K; Parks D
    Obes Facts; 2012; 5(4):485-94. PubMed ID: 22854341
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.